FDA Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
FDA approves Acorda's new MS drug
January 22, 2010 — 4:49pm ET
By John Carroll
The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with a placebo. This is the first drug approved for this use.
Read the FierceBiotech full article